Welcome to our dedicated page for Zivo Bioscience news (Ticker: ZIVO), a resource for investors and traders seeking the latest updates and insights on Zivo Bioscience stock.
ZIVO Bioscience develops therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures. News about ZIVO centers on its biotech and agtech R&D platform, Zivolife™ algal biomass for human nutrition, and animal-health applications built around proprietary active ingredients, algal and bacterial strains, and cultivation and production techniques.
Company updates commonly cover commercial manufacturing and distribution relationships, poultry health research, University of Delaware studies involving low pathogenicity avian influenza, coccidiosis treatment licensing discussions, immune-enhancing biologics for poultry, shareholder communications, capital needs, and public-company reporting status.
ZIVO Bioscience, Inc. (OTCQB: ZIVO) reports favorable results from a 42-day study of its coccidiosis treatment in broiler chickens. The study, conducted with a major global animal health company, showed that ZIVO's non-antibiotic, immune-modulating product significantly improved growth performance and reduced clinical signs of disease when used in combination with existing treatments. Chickens treated with ZIVO's product alongside an ionophore or vaccination achieved feed conversion ratios comparable to healthy, uninfected birds. This demonstrates the product's potential to enhance current treatment options and its standalone treatment capabilities for coccidiosis, a major challenge in poultry production.
ZIVO Bioscience (NASDAQ: ZIVO) announced the start of a 42-day confirmatory study in partnership with a major global animal health company to validate its non-antibiotic coccidiosis treatment for broiler chickens. This study, building on previous positive results, aims to ensure the product's effectiveness under commercial poultry production conditions. The study compares ZIVO's product with traditional ionophore-based treatments and explores combinations with coccidiosis vaccines. The goal is to provide a sustainable, antibiotic-free solution to address the $10 billion annual loss in the poultry industry due to coccidiosis. The results are expected by September.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.